S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Is this AI's biggest breakthrough to date? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Is this AI's biggest breakthrough to date? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Is this AI's biggest breakthrough to date? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Is this AI's biggest breakthrough to date? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Aura Biosciences (AURA) Competitors

$8.73
-0.07 (-0.80%)
(As of 02/22/2024 ET)

AURA vs. HARP, ORTX, EPIX, MRSN, AVXL, OMGA, DRTS, URGN, MESO, and REPL

Should you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Harpoon Therapeutics (HARP), Orchard Therapeutics (ORTX), ESSA Pharma (EPIX), Mersana Therapeutics (MRSN), Anavex Life Sciences (AVXL), Omega Therapeutics (OMGA), Alpha Tau Medical (DRTS), UroGen Pharma (URGN), Mesoblast (MESO), and Replimune Group (REPL). These companies are all part of the "medical" sector.

Aura Biosciences vs.

Harpoon Therapeutics (NASDAQ:HARP) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Harpoon Therapeutics presently has a consensus price target of $24.75, suggesting a potential upside of 7.80%. Aura Biosciences has a consensus price target of $21.00, suggesting a potential upside of 140.55%. Given Harpoon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Harpoon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harpoon Therapeutics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aura Biosciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Harpoon Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Harpoon Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.27 beat Harpoon Therapeutics' score of 0.96 indicating that Harpoon Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harpoon Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aura Biosciences has lower revenue, but higher earnings than Harpoon Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harpoon Therapeutics$31.92M12.18-$67.73M-$8.76-2.62
Aura BiosciencesN/AN/A-$58.76M-$1.94-4.50

Aura Biosciences has a net margin of 0.00% compared to Aura Biosciences' net margin of -81.68%. Harpoon Therapeutics' return on equity of -40.83% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Harpoon Therapeutics-81.68% -893.55% -45.98%
Aura Biosciences N/A -40.83%-35.31%

Harpoon Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Harpoon Therapeutics received 81 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 59.24% of users gave Harpoon Therapeutics an outperform vote while only 46.15% of users gave Aura Biosciences an outperform vote.

CompanyUnderperformOutperform
Harpoon TherapeuticsOutperform Votes
93
59.24%
Underperform Votes
64
40.76%
Aura BiosciencesOutperform Votes
12
46.15%
Underperform Votes
14
53.85%

74.0% of Harpoon Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Aura Biosciences shares are owned by institutional investors. 17.0% of Harpoon Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Harpoon Therapeutics beats Aura Biosciences on 9 of the 16 factors compared between the two stocks.


Get Aura Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AURA vs. The Competition

MetricAura BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$334.01M$2.69B$5.14B$7.52B
Dividend YieldN/A2.38%2.90%3.86%
P/E Ratio-4.507.76133.6418.30
Price / SalesN/A320.013,084.73162.71
Price / CashN/A29.2289.2653.30
Price / Book1.313.914.304.60
Net Income-$58.76M$60.18M$112.74M$207.29M
7 Day Performance-1.24%-0.19%0.43%-1.02%
1 Month Performance14.27%9.83%6.41%3.31%
1 Year Performance-16.54%5.41%8.13%3.73%

Aura Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HARP
Harpoon Therapeutics
2.5206 of 5 stars
$22.39
-0.1%
$24.75
+10.5%
+187.0%$379.06M$31.92M-2.5653Positive News
ORTX
Orchard Therapeutics
1.2546 of 5 stars
$16.70
+0.3%
$21.67
+29.7%
+204.5%$380.09M$22.66M-17.77166High Trading Volume
EPIX
ESSA Pharma
2.5495 of 5 stars
$8.68
-5.1%
$16.50
+90.1%
+144.5%$384.00MN/A-14.7150
MRSN
Mersana Therapeutics
4.1343 of 5 stars
$3.63
-4.5%
$7.17
+97.4%
-34.9%$438.18M$26.58M-2.04228Upcoming Earnings
Positive News
Gap Down
AVXL
Anavex Life Sciences
3.7375 of 5 stars
$5.36
-5.5%
$40.00
+646.3%
-50.4%$440.11MN/A-9.9340
OMGA
Omega Therapeutics
3.2768 of 5 stars
$3.89
-9.3%
$11.40
+193.1%
-38.0%$214.50M$2.07M-1.87116
DRTS
Alpha Tau Medical
2.0323 of 5 stars
$3.07
+0.3%
$12.00
+290.9%
-13.0%$212.97MN/A-8.7794
URGN
UroGen Pharma
4.1653 of 5 stars
$19.24
-0.5%
$46.00
+139.1%
+80.1%$451.18M$64.36M-4.55192
MESO
Mesoblast
1.8769 of 5 stars
$2.01
-0.5%
$14.25
+609.0%
-68.5%$204.08M$7.50M-1.7983Upcoming Earnings
REPL
Replimune Group
4.6448 of 5 stars
$7.65
-1.0%
$39.25
+413.1%
-66.6%$469.63MN/A-2.42284Gap Down

Related Companies and Tools

This page (NASDAQ:AURA) was last updated on 2/23/2024 by MarketBeat.com Staff